Make that 2 new sick­le cell dis­ease block­buster hope­fuls OK’d by the FDA in just a few days

Just days af­ter No­var­tis scored a ‘break­through’ OK with their new drug crizan­l­izum­ab (Adakveo) to pre­vent va­so-oc­clu­sive crises (VOCs) among sick­le cell dis­ease pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.